that cause hexosaminidase A enzyme deficiency. 3 It is 100 times more common in Ashkenazi (European) Jews (carrier frequency, 1 in 27) than in general populations (carrier frequency, 1 in 250). 4 Affected babies appear normal at birth, then experience slow neurological decline and death in infancy (infantile TSD) or early childhood (intermediate TSD) . No cure or effective treatment exists.
Preconception genetic screening programs for TSD have been introduced in Jewish communities worldwide to determine individuals' carrier status. [5] [6] [7] [8] Ninety-nine per cent of TSD cases among Jewish people are caused by three known HEXA mutations. 9 Prospective identification of risk allows individuals and couples to make informed decisions about reproduction.
Based on international best-practice principles, 8, 10, 11 Australian genetic screening programs for TSD 12 Jewish-community-funded screening is free to students and uptake is high (99.6%). 13 Screening programs offer testing for additional conditions relevant to the target community, including Fa nco ni ana emia , famili al dysautonomia, Canavan disease, Bloom syndrome, glycogen storage disease type 1a, mucolipidosis type IV, Niemann-Pick disease type A and cystic fibrosis.
An important measure of the success of a genetic screening program is the reduction of target disease incidence over time. Other measures of success include access to and uptake of screening in the target population. 14 Here, we report the outcomes of Jewish screening programs for TSD on the incidence of TSD-affected births in Sydney and Melbourne from 1995 to 2011, inclusive.
Methods
We retrospectively audited all TSD cases diagnosed in Sydney and Melbourne from 1995 through 2011. All samples were processed by one or more of three Australian laboratories (PaLMS, Pathology North, NSW Health Pathology, Sydney; VCGS, Melbourne; and SA Pathology, Adelaide). Laboratory records from these centres pertaining to each case were reviewed. Records of cascade screening (ie, systematic screening of relatives of affected infants) were identified. We audited all laboratory testing for TSD case diagnosis and carrier screening during the study period. This included diagnosis of TSD cases, cascade screening and s cr ee n i n g p ro g r am re f e r ra l s . Between 50% and 70% of Jewish high school students attend Jewish high schools that participate in TSD screening programs. Within TSD screening programs, there is 99% Tay Sachs disease in Australia: reduced disease incidence despite stable carrier frequency in Australian Jews uptake among students offered screening.
Parents of a child with TSD are routinely asked about Jewish heritage, and this information was obtained from laboratory records, medical records and clinical genetics files. Data from testing laboratories and medical records were cross-referenced to eliminate duplication of cases.
We identified all TSD cases diagnosed and obtained the medical and laboratory records for audit. For all TSD cases identified, parental TSD carrier results were on record. We cross-referenced case and cascade screening results with screening program data. Although our audit of laboratory results identified family members of TSD-affected Jewish children who chose to undertake cascade screening and were found to be TSD carriers, no further analysis was performed on the results of extended cascade screening.
Statistical analysis
We obtained summary statistics for births registered in Sydney and Melbourne in 1995-2010. [15] [16] [17] Births for 2011 (Australian Bureau of Statistics
[ABS] unpublished data) were estimated based on consecutive data for the previous 15 years. [15] [16] [17] Jewish births for 1995-2010 were proportionally estimated from the 2006 Australian census report, 18, 19 and we used the number of 0-4-year-olds identified as Jewish as a proxy measure for births during this 5-year census period.
De-identified data relating to all students screened for TSD in Sydney in 1995-2011 and Melbourne in 1998-2011 were used to calculate TSD carrier frequency among Jewish students. This was used to model expected TSD-affected births among Jewish Australians. Carrier frequency for TSD in the general Australian population has not been measured. We used the World Health Organization estimate for TSD carrier frequencies in mixed populations (1 in 250 or 0.4%) 20 to model expected TSD-affected births among non-Jewish Australians.
The predicted numbers of infants born with TSD in Jewish and nonJewish Australians were calculated using the Hardy-Weinberg equation. 21 All statistical analyses were conducted using SPSS version 15.0 (IBM SPSS Statistics). The observed ratio of Jewish to non-Jewish TSD-affected births was 1:5 compared with the expected ratio of 1:2. No Jewish TSD carrier identified through screening has had a TSD-affected child.
Our audit showed that no parents of TSD-affected Jewish children had participated in screening, and no screening program participants were parents of TSD-affected children.
Discussion
Twenty years after the introduction of TSD carrier testing in Australia, 13 there have been fewer than expected Jewish TSD-affected births (Box 3). Further, no genetic carrier identified through screening has had a TSD-affected child. As many of these individuals, now aged 16-38 years, have not commenced and/or completed their families, the full impact of the screening program is yet to be realised. During the study period, most extended families of TSD-affected infants underwent cascade genetic screening, and no parents of an infant with TSD had further TSD-affected children. This is a strong demonstration of the effectiveness of community genetic screening for TSD, supported by appropriate laboratory testing infrastructure.
Current Jewish Australian screening program carrier frequencies are comparable to international Jewish carrier frequencies from 1970 to the present. 5 TSD predominantly affects those of Ashkenazi Jewish ancestry. Of 4105 Australian Jewish high school students screened for TSD in 1995-2007, 78% of participants and 95% of carriers were Ashkenazi. 22 TSD carrier fre qu enc ie s we re 1 in 25 fo r Ashkenazi Jews and 1 in 97 for those of mixed and non-Ashkenazi Jewish heritage. 22 No distinction is made in census data between Ashkenazi and other Jewish Australians, so subpopulation analysis was not performed.
The ABS and Jewish community organisations estimate that Jewish Australians underreport their religion in the census, and usually apply a correction factor of 20% (Eckstein G. Unpublished report; copies available on re qu e st from h t tp :/ / ww w. jca.org.au) We did not apply any correction factor to estimates of Jewish births or expected numbers of Jewish TSD cases.
Our study has limitations relating to the rarity of TSD, the low disease frequency and the small size of the Australian Jewish population. These factors prevented the reduction in observed Jewish TSD cases reaching statistical significance in our study. To demonstrate a significant reduction in cases, it would take 70 years to observe around 12 Jewish TSD cases, using the Poisson model. 23 TSD testing is now less invasive, 24 and the cost of laboratory testing has fallen over the 16-year period described in this study. Outreach screening strategies to extend the benefits of TSD preconception screening to a wider target population should be considered.
Overall, we found that since TSD screening commenced in Australia, the number of observed TSD cases in Jewish Australians has halved compared with predictions, while carrier frequency remains high (1 in 31). Preconception carrier screening, supported by community education and the appreciation of autosomal recessive inheritance are the likely key factors explaining the fewer than expected Jewish babies born with TSD.
